Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study
Huiqiang Huang(Sun Yat-sen University), Jun Zhu(Peking University), Grace Gao(Northumbria University), Ming Yao(Anhui University), Su‐Peng Yeh(China Medical University), Soon Thye Lim(National University of Singapore), DocHyun Yoon(Asan Medical Center), Seok‐Goo Cho(The Catholic University of Korea Seoul St. Mary's Hospital), Yuqin Song(Peking University), Hyeon‐Seok Eom(National Cancer Center), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Tae Min Kim(Seoul National University Hospital), Jin Seok Kim(University of Ulsan), Jie Jin(First Affiliated Hospital Zhejiang University), Ming Qi(Janssen (United States)), Lijia Zhang(Fuzhou University), Shizhou Liu, Won-Seog Kim(Samsung Medical Center), Yok‐Lam Kwong(Queen Mary Hospital)
Cited by 11
Related Papers
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
|Blood|2011|431
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
|New England Journal of Medicine|2022|342
Polyethylene glycol-grafted poly-l-lysine as polymeric gene carrier
|Journal of Controlled Release|1998|337